California is currently home to 5923 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Los Angeles, San Francisco, San Diego and Sacramento. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
A Study to Learn About a Combined COVID-19 and Influenza Shot in Healthy Adults
Recruiting
The purpose of this clinical trial is to see if combining a licensed COVID-19 vaccine and a licensed influenza vaccine into a single shot is safe and can help produce antibodies to defend the body against both SARS-CoV-2 (the virus that causes COVID-19) and influenza. Participants enrolled in this trial will be healthy adults, 50 years of age or older.
Gender:
All
Ages:
50 years and above
Trial Updated:
02/20/2024
Locations: Orange County Research Center, Tustin, California
Conditions: Influenza, Human, SARS-CoV-2 Infection, COVID-19
Randomized, Double-blinded, Placebo-controlled, Evaluating the Treatment With LB-102 in Patients With Acute Schizophrenia
Recruiting
This is a Phase 2, randomized, double-blind, placebo-controlled, multi-center inpatient study to evaluate the efficacy and safety of LB-102 in adult patients diagnosed with acutely exacerbated schizophrenia. To determine whether LB-102 administered to patients with acutely exacerbated schizophrenia demonstrates antipsychotic efficacy, as determined by a change from Baseline on the Positive and Negative Syndrome Scale (PANSS) total score, compared to placebo at 28 days. The secondary objectives o... Read More
Gender:
All
Ages:
Between 18 years and 55 years
Trial Updated:
02/20/2024
Locations: CelExel Clinical Innovations, Bellflower, California
Conditions: Schizophrenia
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration
Recruiting
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration
Gender:
All
Ages:
60 years and above
Trial Updated:
02/20/2024
Locations: California Retina Consultants (01-026), Bakersfield, California
Conditions: Geographic Atrophy
ACP-204 in Adults With Alzheimer's Disease Psychosis
Recruiting
This is a master protocol for 3 independent, seamlessly enrolling, multicenter, randomized, double-blind, placebo-controlled, parallel-group studies in patients with ADP Substudy 1 (Phase 2) will evaluate efficacy and dose response of ACP-204 30 and 60 mg vs placebo. This substudy will be initiated first. Substudies 2A and 2B (both: Phase 3) will be confirmatory studies of either both doses (ACP-204 30 and 60 mg, respectively) or a single dose from Part 1 vs placebo. Substudies 2A and 2B will b... Read More
Gender:
All
Ages:
Between 55 years and 95 years
Trial Updated:
02/20/2024
Locations: ATP Clinical Research, Costa Mesa, California
Conditions: Alzheimer's Disease Psychosis
Study of an Investigational Pentavalent Meningococcal ABCYW Vaccine in Adults and Adolescents
Recruiting
The purpose of VAN00010 study is to assess the safety and immunogenicity of the investigational pentavalent meningococcal ABCYW vaccine in adults and adolescents. The study duration will be up to 12 months for all participants.
Gender:
All
Ages:
Between 10 years and 25 years
Trial Updated:
02/20/2024
Locations: Smart Cures Clinical Research Site Number : 8400072, Anaheim, California
Conditions: Meningococcal Infection, Healthy Volunteers
Phase 2a Study of Efficacy and Safety of OpSCF in Moderate to Severe Atopic Dermatitis
Recruiting
The purpose of this study is to determine the efficacy and safety of a monoclonal antibody, OpSCF, in the treatment of adults with moderate to severe Atopic Dermatitis (Eczema). OpSCF will be compared to a placebo. OpSCF or placebo will be administered every 2 weeks for 14 weeks, and the efficacy will be assessed two weeks later. After that, subjects may choose to enter an Open Label Extension phase in which all subjects will receive OpSCF every 4 weeks for 40 additional weeks.
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
02/20/2024
Locations: First OC Dermatology Research, Fountain Valley, California
Conditions: Atopic Dermatitis
A Post-Market Study for Long-Term Effectiveness and Safety of the NTX100 for RLS
Recruiting
Multi-center post-market, observational study to assess the long-term effectiveness and safety of the NTX100 TOMAC System for patients with Restless Legs Syndrome.
Gender:
All
Ages:
21 years and above
Trial Updated:
02/20/2024
Locations: Mark J Buchfuhrer, MD Office, Downey, California
Conditions: Restless Legs Syndrome
A Study to Investigate the Effect on Lung Function of an Approved COPD Treatment (BGF, With HFA Propellant) Compared to BGF Formulated With a New Propellant (HFO) in Participants 40 to 80 Years of Age With COPD
Recruiting
The purpose of this study is to demonstrate that the lung function effect from orally inhaled BGF delivered via HFO propellant is equivalent to the lung function effect from orally inhaled BGF delivered via HFA propellant in participants with COPD. The study duration for each participant will be approximately 15 to 16 weeks and consist of: A screening and placebo run-in period of approximately 2 weeks prior to first dosing Three treatment periods of approximately 4 weeks each (one period for ea... Read More
Gender:
All
Ages:
Between 40 years and 80 years
Trial Updated:
02/20/2024
Locations: Research Site, Northridge, California
Conditions: COPD (Chronic Obstructive Pulmonary Disease)
Study of INKmune in Patients With mCRPC (CaRe Prostate)
Recruiting
This is an open-label, phase I/IIa dose escalation and expansion study of INKmune in men with mCRPC. INKmune is administered to patients intravenously over three doses, at least one-week apart. The study will consist of two stages.
Gender:
Male
Ages:
18 years and above
Trial Updated:
02/20/2024
Locations: VA Greater Los Angeles Healthcare System, Los Angeles, California
Conditions: Cancer, Metastatic Castration-resistant Prostate Cancer, mCRPC
A Study to Compare the Efficacy and Safety of Idecabtagene Vicleucel With Lenalidomide Maintenance Therapy Versus Lenalidomide Maintenance Therapy Alone in Adult Participants With Newly Diagnosed Multiple Myeloma Who Have Suboptimal Response After Autologous Stem Cell Transplantation
Recruiting
The purpose of this study is to compare the efficacy, safety, and tolerability of ide-cel with lenalidomide (LEN) maintenance to that of LEN maintenance alone in adult participants with Newly Diagnosed Multiple Myeloma (NDMM) who have achieved a suboptimal response post autologous stem cell transplantation (ASCT).
Gender:
All
Ages:
18 years and above
Trial Updated:
02/20/2024
Locations: UCLA Hematology/Oncology - Westwood (Building 200 Suite 120), Los Angeles, California
Conditions: Multiple Myeloma
Amulet™ ADVANCE LAA
Recruiting
This is a prospective, multicenter, observational study intended to characterize real-world outcomes on the commercially available Amulet device in the United States. The study will enroll approximately 1000 subjects at up to 50 US clinical sites. Subjects will be followed through 24 months in accordance with each site's standard care practices.
Gender:
All
Ages:
18 years and above
Trial Updated:
02/20/2024
Locations: San Diego Cardiac Center, San Diego, California
Conditions: Atrial Fibrillation, Stroke, Bleeding
Donor-Derived Anti-CD33 CAR T Cell Therapy (VCAR33) in Patients With Relapsed or Refractory AML After Allogeneic Hematopoietic Cell Transplant
Recruiting
This is a Phase 1/2, multicenter, open-label, first-in-human (FIH) study of donor-derived anti-CD33 Chimeric Antigen Receptor (CAR) T cell therapy (VCAR33) in patients with relapsed or refractory Acute Myeloid Leukemia (AML) after human leukocyte antigen (HLA)-matched allogeneic hematopoietic cell transplant (alloHCT).
Gender:
All
Ages:
18 years and above
Trial Updated:
02/20/2024
Locations: University of California San Diego Moores Cancer Center, La Jolla, California
Conditions: Leukemia, Myeloid, Acute